This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.

Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009

Inclusion Criteria:

• You must have confirmed metastatic or advanced cancer that has not responded to standard therapy or where standard therapy does not exist
• In Part C, patients must have a diagnosis of advanced or metastatic colorectal adenocarcinoma or non-small cell lung cancer, and must have received at least 1 but no more than three prior systemic therapy treatment regimens
• You must be over the age of 18 years old
• You must have a ECOG status performance of 0 or 1
• You must have good organ function
• You must be willing to have skin and/or tumor biopsies

Exclusion Criteria:

• You have had cancer treatment within 4 weeks prior to entering the study or you still have bad side effects from previous therapies
• You have an active infection that requires treatment
• You are HIV positive or have a history of Hepatitis B or C